SPDR Series Trust · net assets $10.7B · 161 holdings as of June 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 94.3% · STIV: 5.6% · DE: 0.1%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $3.35B | $2.15B | $3.52B |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $2.71B | $2.37B | $2.6B |
| Net realized gain (non-derivative) | $275M | $167M | $26.3M |
| Net unrealized appreciation (non-derivative) | $-58.4M | $154M | $1.41B |
The three months of the reporting period, as filed; month 3 ends June 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| State Street Global Advisors STIV | $631M | 5.87% |
| Apogee Therapeutics Inc EC | $160M | 1.49% |
| Moderna Inc EC | $152M | 1.41% |
| Twist Bioscience Corp EC | $151M | 1.41% |
| Oruka Therapeutics Inc EC | $148M | 1.38% |
| Kymera Therapeutics Inc EC | $146M | 1.36% |
| Viking Therapeutics Inc EC | $140M | 1.30% |
| Praxis Precision Medicines Inc EC | $139M | 1.29% |
| Erasca Inc EC | $136M | 1.27% |
| Revolution Medicines Inc EC | $129M | 1.20% |
| Rhythm Pharmaceuticals Inc EC | $129M | 1.20% |
| Cg Oncology Inc EC | $129M | 1.20% |
| Sellas Life Sciences Group Inc EC | $128M | 1.19% |
| Vaxcyte Inc EC | $127M | 1.19% |
| Dianthus Therapeutics Inc EC | $127M | 1.18% |
| Cytokinetics Inc EC | $126M | 1.18% |
| Natera Inc EC | $125M | 1.16% |
| Scholar Rock Holding Corp EC | $124M | 1.16% |
| Roivant Sciences Ltd EC | $124M | 1.16% |
| Mirum Pharmaceuticals Inc EC | $124M | 1.16% |
| Cogent Biosciences Inc EC | $123M | 1.14% |
| Ultragenyx Pharmaceutical Inc EC | $122M | 1.14% |
| Travere Therapeutics Inc EC | $121M | 1.13% |
| Alkermes PLC EC | $119M | 1.11% |
| Krystal Biotech Inc EC | $118M | 1.10% |
| Celcuity Inc EC | $118M | 1.10% |
| Relay Therapeutics Inc EC | $118M | 1.10% |
| Spyre Therapeutics Inc EC | $118M | 1.10% |
| Tg Therapeutics Inc EC | $117M | 1.09% |
| Beam Therapeutics Inc EC | $116M | 1.08% |
| Insmed Inc EC | $116M | 1.08% |
| Protagonist Therapeutics Inc EC | $115M | 1.07% |
| Arrowhead Pharmaceuticals Inc EC | $115M | 1.07% |
| Vera Therapeutics Inc EC | $114M | 1.06% |
| Vertex Pharmaceuticals Inc EC | $113M | 1.06% |
| Madrigal Pharmaceuticals Inc EC | $113M | 1.06% |
| Abbvie Inc EC | $111M | 1.04% |
| Biogen Inc EC | $111M | 1.03% |
| Ptc Therapeutics Inc EC | $111M | 1.03% |
| Halozyme Therapeutics Inc EC | $111M | 1.03% |
| Uniqure Nv EC | $110M | 1.03% |
| Bridgebio Pharma Inc EC | $110M | 1.02% |
| Crispr Therapeutics Ag EC | $110M | 1.02% |
| Immunitybio Inc EC | $109M | 1.02% |
| Summit Therapeutics Inc EC | $109M | 1.01% |
| Ionis Pharmaceuticals Inc EC | $108M | 1.00% |
| Incyte Corp EC | $107M | 1.00% |
| Amgen Inc EC | $107M | 0.99% |
| Neurocrine Biosciences Inc EC | $104M | 0.97% |
| Gilead Sciences Inc EC | $104M | 0.96% |
| Regeneron Pharmaceuticals Inc EC | $103M | 0.96% |
| Exelixis Inc EC | $103M | 0.96% |
| Alnylam Pharmaceuticals Inc EC | $103M | 0.96% |
| Biomarin Pharmaceutical Inc EC | $101M | 0.94% |
| Acadia Pharmaceuticals Inc EC | $101M | 0.94% |
| Nuvalent Inc EC | $99.7M | 0.93% |
| Immunovant Inc EC | $99.3M | 0.92% |
| United Therapeutics Corp EC | $99.2M | 0.92% |
| Intellia Therapeutics Inc EC | $97.4M | 0.91% |
| Grail Inc EC | $97.3M | 0.91% |
Showing top 60 of 161 holdings.
Loading...
